rdf:type |
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0020268,
umls-concept:C0022614,
umls-concept:C0025242,
umls-concept:C0025266,
umls-concept:C0030685,
umls-concept:C0033371,
umls-concept:C0034656,
umls-concept:C0391871,
umls-concept:C0680255,
umls-concept:C1280500,
umls-concept:C1283071,
umls-concept:C1707455,
umls-concept:C1963578
|
pubmed:issue |
5
|
pubmed:dateCreated |
2001-4-3
|
pubmed:abstractText |
N-methyl D-aspartate (NMDA)-antagonists decrease neurotoxicity by inhibiting Ca2+ influx which is of interest for the treatment of acute cerebrovascular insults and chronic neurodegenerative disorders. Currently, there is no surrogate marker for quantification of NMDA-receptor-mediated drug effects, which hampers dose-finding clinical studies. As prolactin and cortisol liberation is in part influenced through NMDA-receptors we investigated whether the elevation of prolactin or cortisol plasma levels is a class effect of NMDA-antagonists and might be an appropriate marker for studying NMDA-antagonistic potency. Fifteen healthy male volunteers participated in this placebo-controlled, randomized, three-way crossover trial. Ketamine (0.5mg/kg), memantine (0.16 mg/kg; i.e., a well tolerated standard dose) or placebo were infused over 60 min. Ketamine increased serum prolactin and cortisol levels (p < 0.001), whereas memantine and placebo did not affect hormone levels. Further studies are needed to define whether higher doses of memantine or other NMDA antagonists can induce hormone release.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0893-133X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
590-3
|
pubmed:dateRevised |
2011-5-18
|
pubmed:meshHeading |
pubmed-meshheading:11282259-Adult,
pubmed-meshheading:11282259-Blood Pressure,
pubmed-meshheading:11282259-Cross-Over Studies,
pubmed-meshheading:11282259-Drug Tolerance,
pubmed-meshheading:11282259-Excitatory Amino Acid Antagonists,
pubmed-meshheading:11282259-Heart Rate,
pubmed-meshheading:11282259-Humans,
pubmed-meshheading:11282259-Hydrocortisone,
pubmed-meshheading:11282259-Ketamine,
pubmed-meshheading:11282259-Male,
pubmed-meshheading:11282259-Memantine,
pubmed-meshheading:11282259-Nerve Degeneration,
pubmed-meshheading:11282259-Neuroprotective Agents,
pubmed-meshheading:11282259-Prolactin,
pubmed-meshheading:11282259-Receptors, N-Methyl-D-Aspartate
|
pubmed:year |
2001
|
pubmed:articleTitle |
Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial.
|
pubmed:affiliation |
Department of Clinical Pharmacology, Vienna University School of Medicine, Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|